What is Merion?
Founded in 2007 and headquartered in California, Merion, Inc. operates as a public biotechnology firm specializing in the development and manufacturing of plant-based, small-molecular nutrition supplements. The company distinguishes itself through the integration of advanced cell-carrier technology, which enhances the bioavailability and efficacy of its product portfolio. By bridging the gap between rigorous scientific research and consumer-facing e-commerce platforms, Merion has successfully captured a growing share of the health-conscious market. Its business model relies on a dual-channel distribution strategy, utilizing both digital storefronts and traditional retail pathways to maximize reach and drive year-over-year revenue growth.
How much funding has Merion raised?
Merion has raised a total of $287K across 2 funding rounds:
Debt
$150K
Debt
$137K
Debt (2020): $150K with participation from PPP
Debt (2021): $137K led by PPP
Key Investors in Merion
PPP
Public-Private Partnership
What's next for Merion?
With the recent influx of capital, Merion is positioned to accelerate its R&D initiatives and expand its footprint in the global nutrition sector. The strategic focus will likely center on scaling the production of its high-tech molecular supplements to meet rising consumer demand. Furthermore, the company is expected to enhance its e-commerce infrastructure, optimizing its supply chain to support broader market penetration. As Merion continues to leverage its proprietary cell-carrier technology, the firm remains focused on long-term value creation for shareholders, balancing aggressive market expansion with the maintenance of its high-quality manufacturing standards.
See full Merion company page
